Tonix Pharmaceuticals is a clinical-stage pharmaceutical
company focused on the development of next-generation medications for disorders
of the central nervous system. The company’s leading product candidate, Tonmya,
is currently being evaluated in a phase III clinical study for the treatment of
fibromyalgia, as well as a phase II clinical study for the treatment of
post-traumatic stress disorder. Additionally, Tonix’s product pipeline includes
TNX-201, which is currently being studied in a phase II proof-of-concept trial
for the treatment of episodic tension-type headaches.
“Having three large, adequate and well-controlled clinical
studies in high-value therapeutic indications simultaneously ongoing validates
our business model of developing next generation medicines for significant
unmet needs in a capital-efficient manner,” Dr. Seth Lederman, chairman and
chief executive officer of Tonix, stated in a news release.
When commercialized for the treatment of fibromyalgia,
Tonmya will give Tonix access to a large and relatively underserved market
within the pharmaceutical industry. According to the Centers for Disease
Control and Prevention, fibromyalgia affects an estimated five million
Americans. Recent evidence suggests that poor sleep quality likely plays a
fundamental role in the development and persistence of the disorder, which is
characterized by chronic widespread pain and abnormal pain processing. Tonmya
addresses this issue by performing as a low-dose sleep aid to improve quality
of rest, effectively minimizing the effects of fibromyalgia symptoms. Top-line
data from the company’s ongoing clinical study is expected in the second half
of 2016.
In June, Tonix substantially increased its potential for
short-term growth within the pharmaceutical industry by initiating its phase II
study of TNX-201. Designed to establish efficacy and safety evidence to support
future studies, the results of this trial could clear the way for the continued
development of the first new prescription pharmaceutical approved to treat
episodic tension-type headaches in more than 40 years.
“Approximately 75 million people in the U.S. suffer from
frequent episodic tension-type headache, a condition that is estimated to be
three times as prevalent as migraine,” continued Lederman. “If approved by the
FDA, TNX-201 may become the only non-narcotic prescription medicine for
episodic tension-type headache.”
Moving forward, Tonix’s promising product pipeline could
provide a formidable platform for the company to realize tremendous market
growth. For prospective shareholders, the company’s ongoing clinical trials and
the immense market potential of its drug candidates combine to make Tonix an
intriguing investment opportunity in the months to come.
For more information, visit www.tonixpharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
